ALN-F1202 / Alnylam, Regeneron - LARVOL DELTA

ALN-F1202-HV-2412: Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults. (clinicaltrialsregister.eu) - P1 | N=56 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=40 ➔ 56

Enrollment change • Enrollment closed

Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function. (PubMed, Thromb Res) - "Our findings support that reduction of plasma Factor XII by ALN-F12 provided thrombo-protective effects with no increased bleeding risk in rodent models of thrombosis and hemostasis."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism